Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?

Expert review of clinical pharmacology - 1 Nov 2020

Deligiorgi Maria V, Panayiotidis Mihalis I, Trafalis Dimitrios T

Abstract excerpt

INTRODUCTION: Denosumab is a human monoclonal antibody inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL). Initially approved as antiosteοporotic agent, denosumab is being currently pursued as a candidate for drug repurposing in oncology, especially breast cancer. AREAS COVERED: The present review provides an overview of the therapeutic potential of denosumab in breast cancer beyond...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Disease-Free Survival

Share to Drug Repositioning

Share to Mutation

Share to RANK Ligand

Source

Identifiers

PMID: 33070648
DOI: 10.1080/17512433.2020.1839416

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?PMID 33070648Read ↗

RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers.Semantic proximity Read ↗

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.Semantic proximity Read ↗

Denosumab: mechanism of action and clinical outcomesSemantic proximity Read ↗

RANKL/RANK: from bone loss to the prevention of breast cancer.Semantic proximity Read ↗

OSTEONECROSIS OF THE JAW (ONJ) IN BREAST CANCER PATIENTS: EFFECT OF PREVENTIVE MEASURES IN A MONOINSTITUTIONAL EXPERIENCESemantic proximity Read ↗

RANKL and RANK in Cancer TherapySemantic proximity Read ↗

RANKL inhibition with denosumab improves fibrous dysplasia by decreasing lesional cell proliferation and increasing osteogenesisSemantic proximity Read ↗

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.Semantic proximity Read ↗

Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical ApplicationsSemantic proximity Read ↗

Denosumab-Related Osteonecrosis of the Jaw: a five year monocentric retrospective study of Ancona General HospitalSemantic proximity Read ↗

Prevention of breast cancer by RANKL/RANK blockade.Semantic proximity Read ↗

The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.